Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Mar 03, 2021 10:18pm
84 Views
Post# 32712099

RE:RE:I'm going to guess ...

RE:RE:I'm going to guess ...
longrun86 wrote: Your post gave me a good laugh.

I am relatively new to this board but it certainly has some interesting characters.

I was hoping that this board would have more posts that would help me understand the business (ie: industry, target markets, ROW strategy, competitors, drug distribution strategies, etc.).

Sincerely,

LR


=======

Hey Longrun.
I'm sure we'll eventually have lots to talk about.
I recently spoke with management and I will update you on relevant items as we go.
LATAM is the focus and we have lots to optimize there - unfortunately COVID through a wrench into those plans and things can't be done as quickly as they'd like.
The focus will likely remain on LATAM for growth and this quiet period seems to indicate they are working on snagging bigger deals.
Unfortunately ... don't know what happens next.

If you haven't seen the 2014 video, I recomment you watch it and pay close attention to the graph at the end of the video.  It tells you what you need to know.  Actually, Goodman does a good job telling you the way it is - no sugar coatings.

It took Goodman 12 years the first time to get his share price really moving.  It also took him 15 years to start the ROW program.

This time - ROW started 5+ years in.  In a way, ROW started on day one with Knight, if you look at some of the licenses that were acquired for ROW countries.

Hope this helps.

https://www.canadianvaluestocks.com/jonathan-goodman/

<< Previous
Bullboard Posts
Next >>